Research News and Research

RSS

Media outlets look ahead to Obama's trip to India

Several media outlets looked ahead to President Barack Obama's scheduled visit to India later this week, as part of his Asia-Pacific tour.

2 Nov 2010

New findings pave way to improve early detection of ovarian cancer

A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

2 Nov 2010

3 states to vote on health insurance mandate

Kaiser Health News staff writer Aimee Miles reports: "Voters in Arizona, Colorado and Oklahoma will have the chance Tuesday to repudiate the new health care law's keystone provision, one that requires almost everyone to have health insurance or face a tax penalty beginning in 2014" (Miles, 10/30).

2 Nov 2010

Non-dividing cells can also start cancer

Cancer Research UK scientists have found that non-dividing cells are able to kick-start some cancers, challenging a long held belief that only dividing cells, like stem cells, cause the disease, according to research published online in PNAS today (Monday).

2 Nov 2010

Races make final health overhaul messages clear as Election Day nears

Candidates push their final messages for Tuesday's elections, while the congressional debate over the health care overhaul still reverberates.

2 Nov 2010

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists.

2 Nov 2010

Health law, elections trigger questions about Medicare payment issues

While most people are focused on the midterm elections Tuesday, the American Medical Association is gearing up for the lame-duck congressional session scheduled to start Nov. 15.

2 Nov 2010

National Jewish Health's chronic urticaria diagnostic assay receives US patent

National Jewish Health has received a US patent for a method of detecting autoimmune chronic urticaria, which will help assure many patients that dramatic changes in lifestyle are not needed to treat the condition.

2 Nov 2010

PAREXEL first quarter revenue increases 13.9% to $295.8 million

PAREXEL International Corporation today announced its financial results for the first quarter ended September 30, 2010.

From Parexel 2 Nov 2010

Alcohol - the worst drug!

A new study shows that alcohol abuse is by far the worst habit to have when compared to other recreational drugs like crack or heroin. Neuropharmacologist David Nutt, of Imperial College London who is also a former British government drug advisor and his team rated 20 different drugs on a scale that takes into account the various harms caused by a drug. Drugs are rated on the nine harms a drug causes to an individual and seven harms a drug causes to the society. The scale was developed by a panel of experts called the Independent Scientific Committee on Drugs (ICSD), ranges from 0 (no harm) to 100 (greatest possible harm). It is weighted so that a drug that scores 50 is half as harmful as a drug that scores 100.

1 Nov 2010

AHRQ: Hospital admissions for adverse drug reactions have doubled

News outlets report on the hospital industry, including admission rates, mergers and quality improvement programs.

1 Nov 2010

Open enrollment brings higher premiums for 2011

As open enrollment for many employer-sponsored health plans approaches, workers are faced with higher premiums in 2011, yet again, MSNBC reports. "The increase is typical of what workers have seen in [the] last three years — around 10 percent. But what's different this year is some employers aren't just blaming the usual suspects for rising premiums — unhealthy workers, over-paid doctors and hospitals, and a bad economy. Now insurance experts and employers are also blaming health care reform.

1 Nov 2010

IMRT safe and effective treatment for paranasal tumors: Study

Treating paranasal sinus cancer with three-dimensional radiation that conforms to the shape of the tumor-a technique that minimizes side effects such as severe dry mouth and vision problems-is safe and effective, research at Fox Chase Cancer Center shows. Aruna Turaka, M.D., radiation oncologist at Fox Chase, will present the results on November 2nd at the annual meeting of the American Society for Radiation Oncology.

1 Nov 2010

Insurance costs continue to surge

The cost of health insurance continues to surge, and the effect of the new health law is still unclear, The Atlanta Journal-Constitution reports.

1 Nov 2010

Planning Accountable Care Organizations

American Medical News: "The National Committee for Quality Assurance is seeking input from the public on draft accountable care organization standards," which "were drafted by the organization's Accountable Care Organization Task Force comprising representatives from large integrated health care systems, academia and the insurance industry. … Establishing ACOs for Medicare and Medicaid beneficiaries is a key part of health system reform legislation" (11/1).

1 Nov 2010

454 Life Sciences and DNA Electronics partner to develop high-throughput DNA sequencing system

454 Life Sciences, a Roche Company, announced today that it has entered an exclusive partnership with DNA Electronics for the development of a low-cost, high-throughput DNA sequencing system. As part of the agreement, Roche has signed a non-exclusive license for relevant IP from DNA Electronics' proprietary semiconductor technology portfolio, which enables sensitive detection of nucleotide incorporation during sequencing.

1 Nov 2010

Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment

Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.

1 Nov 2010

Today's OpEds: Health law and private insurance; Corporate wellness programs; Geriatric mental health

Once again, average health insurance rates are expected to rise by double digits next yearas they have every year since 2002. ... Given that Obama would veto a repeal, we hope the next Congress instead begins the hard work of re-crafting the new law with a goal of breaking the annual spikes in cost (The Denver Post, 11/1).

1 Nov 2010

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

1 Nov 2010

Allergan third quarter diluted loss per share increases to $2.21

Allergan, Inc. today announced operating results for the quarter ended September 30, 2010. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 1, 2010 to stockholders of record on November 10, 2010.

1 Nov 2010